659 related articles for article (PubMed ID: 34659218)
1. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
2. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
5. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
6. A Hypoxia-Related Long Non-Coding RNAs Signature Associated With Prognosis in Lower-Grade Glioma.
Feng Q; Qian C; Fan S
Front Oncol; 2021; 11():771512. PubMed ID: 34869006
[TBL] [Abstract][Full Text] [Related]
7. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma.
Zhang Q; Liu XJ; Li Y; Ying XW; Chen L
Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865
[TBL] [Abstract][Full Text] [Related]
9. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
10. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial RNA modification-based signature to predict prognosis of lower grade glioma: a multi-omics exploration and verification study.
Zhou X; Ling Y; Cui J; Wang X; Long N; Teng W; Liu J; Xiang X; Yang H; Chu L
Sci Rep; 2024 Jun; 14(1):12602. PubMed ID: 38824202
[TBL] [Abstract][Full Text] [Related]
12. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma.
Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB
Front Immunol; 2020; 11():606164. PubMed ID: 33408717
[TBL] [Abstract][Full Text] [Related]
13. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
Front Immunol; 2021; 12():668391. PubMed ID: 34539622
[TBL] [Abstract][Full Text] [Related]
14. Identification of Critical m
Zheng J; Wang X; Qiu Y; Wang M; Yu H; Zhou Z; Wu Z; Jiang X
Biomed Res Int; 2021; 2021():9959212. PubMed ID: 34212046
[TBL] [Abstract][Full Text] [Related]
15. Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma.
Yu H; Gong M; Qi J; Zhao C; Niu W; Sun S; Li S; Hong B; Qian J; Wang H; Chen X; Fang Z
BMC Cancer; 2022 Aug; 22(1):885. PubMed ID: 35964070
[TBL] [Abstract][Full Text] [Related]
16. An Immune-Related lncRNA Signature to Predict Survival In Glioma Patients.
Xia P; Li Q; Wu G; Huang Y
Cell Mol Neurobiol; 2021 Mar; 41(2):365-375. PubMed ID: 32410107
[TBL] [Abstract][Full Text] [Related]
17. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
[TBL] [Abstract][Full Text] [Related]
18. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
20. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]